When stratified the whole population into MS and non-MS subjects, the anti-inflammatory capacity of apoB-depleted plasma was also different in the MS subjects vs non- MS subjects [1.14 vs 0.63 fold increase in VCAM-1 mRNA expression; P = 0.046] (Fig 1B), but was not significantly different between the subjects without hypertension and with hypertension [0.84 vs 0.74 fold increase in VCAM-1 mRNA expression; P = 0.984]. The gene discussed is VCAM1; the disease is myeloid sarcoma.